Jie Zeng

Jie Zeng

Auto-generated profile, based on publicly available information

Jie Zeng

Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
RMRong-Yun Mai
Rong-Yun Mai
JZJie Zeng
Jie Zeng
YMYi-Shuai Mo
Yi-Shuai Mo
RLRong Liang
Rong Liang
YLYan Lin
Yan Lin
JYJia-Zhou Ye
Jia-Zhou Ye
Background: Testing for the presence of liver cirrhosis (LC) is one of the most critical diagnostic and prognostic assessments for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). More non-invasive tools are needed to diagnose LC but the predictive abilities of current models are still inconclusive. This study aimed to develop and validate a novel and non-invasive artificial neural network (ANN) model for diagnosing LC in patients with HBV-related HCC using routine laboratory serological indicators. Methods: A total of 1152 HBV-related HCC patients who underwent hepatectomy were included and randomly divided into the training set (n = 864, 75%) and validation set (n = 288, 25%). The ANN model was constructed from the training set using multivariate Logistic regression analysis and then verified in the validation set. Results: The morbidity of LC in the training and validation sets was 41.2% and 46.8%, respectively. Multivariate analysis showed that age, platelet count, prothrombin time and total bilirubin were independent risk factors for LC (P < 0.05). The area under the ROC curve (AUC) analyses revealed that the ANN model had higher predictive accuracy than the Logistic model (ANN: 0.757 vs Logistic: 0.721; P < 0.001), and other scoring systems (ANN: 0.757 vs CP: 0.532, MELD: 0.594, ALBI: 0.575, APRI: 0.621, FIB-4: 0.644, AAR: 0.491, and GPR: 0.604; P < 0.05 for all) in diagnosing LC. Similar results were obtained in the validation set. Conclusion: The ANN model has better diagnostic capabilities than other commonly used models and scoring systems in assessing LC risk in patients with HBV-related HCC.

1 December 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
JZJie Zeng
Jie Zeng
HHHongyang Huang
Hongyang Huang
MTMinchao Tang
Minchao Tang
ZTZheng Tao
Zheng Tao
KMKaixiang Mo
Kaixiang Mo
RMRongyun Mai
Rongyun Mai
Microvascular invasion (MVI) serves as a well-established prognostic factor for tumor recurrence and reduced survival following curative hepatectomy in hepatocellular carcinoma (HCC). This investigation aims to assess the therapeutic value of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in HCC patients with MVI and delineate the optimal patient subpopulations for this intervention. This retrospective cohort study analyzed patients with MVI in HCC patients who received curative resection from September 2013 to June 2019. After balancing baseline differences between the PA-TACE group and the non-TACE control group using propensity score matching (PSM), the differences in recurrence-free survival (RFS) and overall survival (OS) between the two groups were compared. A multivariate Cox proportional hazards regression model was used to identify independent prognostic factors. Among 440 evaluable patients, PA-TACE demonstrated statistically significant improvements in both RFS and OS compared to non-TACE management, with consistent results observed in both the entire and propensity score-matched cohorts. Multivariate analysis established PA-TACE as an independent protective predictor for both RFS and OS. Subgroup analyses revealed pronounced clinical benefits in patients exceeding Milan criteria and those presenting with high-risk features including serum AFP ≥400 ng/mL, tumor size ≥5 cm, Edmondson-Steiner grade III/IV differentiation, M2-type MVI, or major hepatectomy. Notably, no survival advantage was observed in patients within Milan criteria or BCLC-A/B stages. PA-TACE provides substantial survival enhancement in HCC patients with MVI exceeding Milan criteria or with high-risk features, but offers limited benefit for Milan-eligible cases. Patient selection based on tumor biology is critical for optimizing adjuvant therapy.